Who was studied, and how
One number in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 3 other studies
people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
GLP-1 RAs
control (placebo or standard care, as implied by RCT context)
Probably lowered serum CRP concentrations−2.14
randomisedthe abstract, start to end
… following treatment with GLP-1 RAs (WMD -2.14 (mg/dL), 95% CI -3.51, -0.78, …
← favours treatmentfavours comparator →
could be chanceSerum CRP concentrationsGLP-1 RAs vs control (placebo or standard care, as implied by RCT context)
−2.14−3.51 to −0.78
GLP-1 receptor agonistsInflammation & biomarkers
GLP-1 receptor agonists × inflammation & biomarkershelps?mixed
unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
1 / 6